Sputnik V is the world’s first registered vaccine based on a well-studied human adenoviral vector-based platform. Sputnik V is one of the three vaccines in the world with efficacy of over 90%. – Read More
Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik V – the world’s first registered vaccine against coronavirus.
RDIF and partners facilitated the technology transfer to Laboratorios Richmond for the local production of the vaccine with the first batch manufactured in April 2021.
In August 2021, RDIF and partners will publish initial data on the immunogenicity of the combined use of the AstraZeneca vaccine and the Sputnik V vaccine in Azerbaijan.